SAN DIEGO, April 23, 2019 – Dr. Eric Daniels, Chief Medical Officer (CMO) of Puregraft, is leading the charge in a live event focused on the importance of educating patients to understand all options for breast augmentation and reconstruction.
This event is scheduled for launch on April 26 following the March 25-26 FDA Advisory Committee meeting regarding the benefits and risks of breast implants for breast augmentation and reconstruction.
“RealTalk: BreastReconstruction” will focus on the topic of breast reconstruction and augmentation options. The event is designed to increase awareness around breast surgery and clinical research, while empowering women to speak confidently with their surgeons regarding all implant options available to them.
Dr. Eric Daniels currently serves as the Chief Medical Officer of Puregraft. Dr. Daniels has published several papers on the role of adipose-derived regenerative cells. Dr. Daniels received his Doctor of Medicine degree from the University of California, Los Angeles School of Medicine and his undergraduate degree in Molecular Biology from the University of California, Berkeley.
“The decision to enhance or reconstruct your breasts is one of the most personal choices a woman can make,” said Dr. Daniels. “Patients deserve as much information as possible when choosing a procedure that’s right for them. Natural fat transfer is increasingly popular among patients seeking a safe option with exceptional aesthetic results.”
“RealTalk: Breast Reconstruction” is sponsored by Puregraft LLC and will take place on the company’s Instagram Page.
About Puregraft LLC
Puregraft LLC is a San Diego-based leader in the development of fat transfer solutions. Our company's flagship technology, Puregraft, is used around the world for cosmetic and reconstructive purposes. Puregraft LLC is devoted to developing fat based technology focused on the emerging regenerative aesthetics market.
